Why Sotera Health is back in focus

Goldman Sachs has initiated coverage of Sotera Health (SHC), just as the company reports first quarter 2026 earnings that topped revenue and profit expectations and gains clarity on Ethylene Oxide related legal exposures.

The recent 1 day share price return of 4.22% to US$16.53, alongside a 90 day share price return of 18.75% and 1 year total shareholder return of 34.39%, points to momentum building as investors reassess Sotera Health after its earnings beat, legal clarity on Ethylene Oxide cases, and the new Goldman Sachs coverage.

If this legal and earnings reset has you looking at where else risks and rewards are shifting in healthcare, it could be a good time to scan 39 healthcare AI stocks

With Sotera Health trading at US$16.53, annual revenue of US$1.19b and net income of US$117.79m, plus a roughly 15% intrinsic discount and 21.66% gap to analyst targets, is there real upside left, or is the market already pricing in future growth?

Most Popular Narrative: 18% Undervalued

With Sotera Health last closing at US$16.53 and the widely followed fair value estimate at US$20.13, the current valuation hinges on how durable earnings and margin assumptions prove to be over time.

Sotera Health's strong cash generation and accelerating deleveraging trend, coupled with high renewal rates and multi-year customer contracts, reinforce revenue and earnings predictability, reduce volatility, and increase financial flexibility to invest in growth projects or strategic acquisitions.

Want to see what is driving that conviction in cash flows and margins? The narrative leans on steady top line growth, rising profitability, and a lower future earnings multiple. Curious which assumptions really carry the fair value story?

Result: Fair Value of $20.13 (UNDERVALUED)

However, that cash flow and margin story still depends on tight execution around Ethylene Oxide regulation and sizable compliance capex that could reduce future flexibility.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: When earnings multiples flash a different signal

The story looks different when you step away from fair value estimates and focus on what the current earnings multiple is saying. At around 40x P/E versus a fair ratio of 26.5x and a global Life Sciences average of 33.8x, the stock screens as expensive on this yardstick. That gap suggests less room for error if earnings or margins fall short. How comfortable are you with paying up for the growth case priced in today?

Next Steps

With mixed signals on valuation, legal risks and growth potential, consider reviewing the details yourself and weighing both sides of the story using 4 key rewards and 2 important warning signs rather than waiting for a consensus to form.

Looking for more investment ideas?

If Sotera Health has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that fit clear, data backed themes using the Simply Wall Street Screener.

• Spot potential bargains by scanning 46 high quality undervalued stocks that pair solid fundamentals with prices that currently sit below their estimated worth.
• Prioritise resilience by checking 63 resilient stocks with low risk scores where balance sheets and risk scores aim to keep surprises to a minimum.
• Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.